Redefining global health priorities: Improving cancer care in developing settings

Affiliations

¹ Institute for Translational Medicine and Novel Therapeutics, Healthnovations International, Houston, TX, USA ; Department of Primary Care Health Sciences, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK ; National Cancer Institute Alliance for Nanotechnology in Cancer, National Institutes of Health, Bethesda, MD, USA.
² Institute for Translational Medicine and Novel Therapeutics, Healthnovations International, Houston, TX, USA.
³ Harvard Global Health Institute, Harvard Medical School, Harvard University, Boston, MA, USA.
⁴ World Bank, WHO International Agency for Research on Cancer, United Nations Development Group, New York, NY, USA.
⁵ National Cancer Institute Alliance for Nanotechnology in Cancer, National Institutes of Health, Bethesda, MD, USA ; Department of Nanomedicine, Houston Methodist Research Institute, Alliance for NanoHealth, Houston, TX, USA.

Review

Asad Moten et al. J Glob Health. 2014 Jun.

. 2014 Jun;4(1):010304.

doi: 10.7189/jogh.04.010304.

¹ Institute for Translational Medicine and Novel Therapeutics, Healthnovations International, Houston, TX, USA ; Department of Primary Care Health Sciences, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK ; National Cancer Institute Alliance for Nanotechnology in Cancer, National Institutes of Health, Bethesda, MD, USA.
² Institute for Translational Medicine and Novel Therapeutics, Healthnovations International, Houston, TX, USA.
³ Harvard Global Health Institute, Harvard Medical School, Harvard University, Boston, MA, USA.
⁴ World Bank, WHO International Agency for Research on Cancer, United Nations Development Group, New York, NY, USA.
⁵ National Cancer Institute Alliance for Nanotechnology in Cancer, National Institutes of Health, Bethesda, MD, USA ; Department of Nanomedicine, Houston Methodist Research Institute, Alliance for NanoHealth, Houston, TX, USA.

Erratum in

Erratum: Moten A, Schafer D, Ferrari M. Redefining global health priorities: Improving cancer care in developing settings. J Glob Health 2014;4: 010304corr1.
[No authors listed] [No authors listed] J Glob Health. 2014 Jun;4(1):010304corr1. doi: 10.7189/jogh.04.010304corr1. J Glob Health. 2014. PMID: 25553758 Free PMC article.

No abstract available

1. World Health Organization. Global battle against cancer won’t be won with treatment alone: effective prevention measures urgently needed to prevent cancer crisis. Geneva: WHO, 2014. Available at: http://www.iarc.fr/en/media–centre/pr/2014/pdfs/pr224_E.pdf. Accessed: 8 April 2014. - PubMed
1. Global Task Force on Expanded Access to Cancer Care and Control in Developing Countries. (GTF.CCC). Cancer medicine prices in low– and middle–income countries. Boston: Management Sciences for Health, 2011. Available at: http://www.msh.org/sites/msh.org/files/ccd_msh.pdf. Accessed: 8 April 2014.
1. American Cancer Society. Global cancer facts & figures, 2nd ed. Atlanta: ACS, 2011. Available at: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/docume.... Accessed: 8 April 2014.
1. The NCD. Alliance. The millennium development goals and non–communicable diseases (NCDs). NCD Alliance, 2013. Available at: http://ncdalliance.org/sites/default/files/rfiles/The%20MDGs%20and%20NCD.... Accessed: 8 April 2014.
1. Farmer P, Frenk J, Knaul FM, Shulman LN, Alleyne G, Armstrong L, et al. Expansion of cancer care and control in countries of low and middle income: a call to action. Lancet. 2010;376:1186–93. doi: 10.1016/S0140-6736(06)69376-8. - DOI - PubMed